Urogen Pharma share price logo

Urogen Pharma

NASDAQ: URGN

Mid Cap

$46.86

+0.06

(+0.13%)

as on

Urogen Pharma Stock Performance

as on August 22, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $45.60
    $47.27
    downward going graph

    2.69%

    Downside

    0.87%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $15.86
    $49.67
    downward going graph

    66.15%

    Downside

    6.00%

    Upside

    downward going graph

Urogen Pharma share price movements today

Previous Close
$46.80
Open
$46.81
Volume
585.7K
Market Cap
$2.3B
Day's Low - High
$45.60 - $47.27
52 Week Low - High
$15.86 - $49.67

Urogen Pharma Historical Returns

1 Month Return
+ 19.86 %
3 Month Return
+ 67.55 %
1 Year Return
+ 144.65 %
3 Year Return
+ 161.64 %
5 Year Return
+ 225.81 %

Urogen Pharma Stock Fundamentals & Key Indicators

Check Urogen Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.3B

EPS (TTM)

-1.98

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-24.3

Industry PE ratio

-13.046547619047619

PEG Ratio

-0.48266424176034406

EBITDA

-70.7M

Revenue (TTM)

188.7M

Profit Margin

90.85%

Return On Equity TTM

81.78%

Urogen Pharma Stock Valuation

Track how Urogen Pharma P/E has moved over time to understand its valuation trends.

Urogen Pharma in the last 5 years

  • Overview

  • Trends

Lowest (-7.34x)

December 31, 2025

Industry (-13.05x)

December 31, 2025

Today (-7.34x)

December 31, 2025

Highest (-1.84x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -7.34x

Urogen Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Urogen Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$2.3B225.81%-24.390.85%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$25.3B-84.24%-7.98-12.57%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Urogen Pharma Stock including INR - Dollar returns

The Urogen Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Urogen Pharma investment value today

Current value as on today

₹2,59,733

Returns

₹1,59,733

(+159.73%)

Returns from Urogen Pharma Stock

₹1,37,747 (+137.75%)

Dollar Impact

₹21,985 (+21.99%)

Analyst Recommendation on Urogen Pharma Stock

Based on 5 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 5 analysts, 80% of analysts recommend a 'BUY' rating for Urogen Pharma. Average target price of $58.25

Urogen Pharma Share Price Target

Get share price movements and forecasts by analysts on Urogen Pharma.

What analysts predicted

19.55%UPSIDE

Target Price

$58.25

Current Price

$46.86

Analyzed by

5 Analysts

Target

$58.25

Urogen Pharma target price $58.25, a slight upside of 19.55% compared to current price of $46.86. According to 5 analysts rating.

Indian Investors' Interest in Urogen Pharma Stock

Search interest for Urogen Pharma Stock has increased by 23% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:23% versus previous 30 day period

Urogen Pharma Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
18
21
25
24
20
24
27
37
50
72
Gross Profit
17
19
22
22
17
20
24
34
46
65
Operating Income
-25
-25
-17
-27
-36
-41
-27
-19
-20
0
EBITDA
-23
-29
-14
-26
-38
-48
-25
-22
-19
-3
Interest Expense
2
3
2
3
4
8
7
13
8
4
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-32
-33
-23
-34
-43
-48
-34
-26
-28
-8
Income Tax Expense
0
0
0
2
0
1
-1
0
-4
5
Net Income
-32
-33
-23
-37
-43
-49
-33
-26
-23
-14
Net Profit Margin
90.80%
89.80%
90.27%
89.94%
88.50%
85.34%
88.07%
91.31%
91.88%
90.93%

Urogen Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
8
1
0
11
48
64
82
90
109
Gross Profit
7
0
0
10
42
56
73
81
97
Operating Income
-19
-77
-109
-126
-92
-79
-65
-96
-124
EBITDA
-19
-77
-108
-122
-108
-76
-60
-95
-135
Interest Expense
-
-
0
0
17
8
14
12
33
Depreciation
0
0
1
2
0
1
1
0
2
Income Before Tax
-19
-75
-105
-125
-109
-108
-98
-124
-153
Income Tax Expense
0
0
-
3
1
1
3
2
0
Net Income
-20
-75
-105
-128
-110
-109
-102
-126
-153
Net Profit Margin
92.65%
-59.84%
100.00%
91.45%
89.27%
88.11%
88.68%
90.18%
88.66%

Urogen Pharma Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-32
-33
-23
-37
-43
-49
-33
-26
-23
-14
Operating Cash Flow
-31
-23
-27
-13
-42
-39
-42
-38
-45
-33
Investing Cash Flow
13
11
-106
60
-25
28
31
27
-20
1
Financing Cash Flow
54
100
39
0
0
0
8
31
65
0
Change in Cash
36
88
-94
47
-67
-11
-2
20
0
-30

Urogen Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-20
-75
-105
-128
-110
-109
-102
-126
-153
Operating Cash Flow
-9
-37
-71
-105
-84
-87
-76
-96
-162
Investing Cash Flow
-36
35
-145
93
4
1
0
-20
61
Financing Cash Flow
61
66
165
16
72
97
116
194
39
Change in Cash
15
64
-51
3
-8
10
39
77
-60

Mutual Funds that own Urogen Pharma Stock

Check out the Mutual Funds with significant holdings in Urogen Pharma.

Funds
Holdings
Shares Held
American Century Mutual Funds, Inc.
1.790038%
874981
Fidelity Salem Street Trust
0.882727%
431482
VANGUARD SCOTTSDALE FUNDS
0.702506%
343389
TIAA-CREF Funds
0.315706%
154319
VANGUARD WORLD FUND
0.241785%
118186

Global Institutional Holdings in Urogen Pharma

Funds
Holdings
iShares
4.47%
Michael Rockefeller
1.02%
Vanguard
0.95%
Fidelity
0.46%
State Street
0.43%

Insights on Urogen Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 6 quarters, 20.25M → 72.45M (in $), with an average increase of 22.2% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, URGN stock has moved up by 62.2%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 5 quarters, -49.94M → -14.35M (in $), with an average increase of 38.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 558.3% return, outperforming this stock by 412.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 466.0% return, outperforming this stock by 325.0%

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
OrganisationUrogen Pharma
Headquarters400 Alexander Park Drive, Princeton, NJ, United States, 08540
IndustryBiotechnology
CEOMs. Elizabeth A. Barrett
E-voting on sharesClick here to vote

Key Management of Urogen Pharma

Name

Title

Ms. Elizabeth A. Barrett

President, CEO & Director

Mr. Jason Drew Smith J.D.

General Counsel, Chief Compliance Officer & Corporate Secretary

Ms. Alison Hardgrove

Senior Vice President of Human Resources

Mr. James Ottinger R.ph.

Executive Vice President of Regulatory Affairs & Quality

Mr. Michael J. Louie M.D., M.P.H., M.Sc.

Chief Development Officer

Mr. Timothy Simon

Senior Vice President of Business Development & Portfolio Strategy

Dr. Mark P. Schoenberg M.D.

Chief Medical Officer

Mr. Christopher Degnan CPA

Chief Financial Officer

Mr. Vincent I. Perrone

Senior Director of Investor Relations

Dr. Marina Konorty Ph.D.

Executive Vice President of Research & Development and Technical Operations

FAQs

What is Urogen Pharma share price today?

Urogen Pharma share price today is $46.86 as on at the close of the market. Urogen Pharma share today touched a day high of $47.27 and a low of $45.60.

What is the 52 week high and 52 week low for Urogen Pharma share?

Urogen Pharma share touched a 52 week high of $49.67 on and a 52 week low of $15.86 on . Urogen Pharma stock price today i.e. is closed at $46.86,which is 5.66% down from its 52 week high and 195.46% up from its 52 week low.

What is Urogen Pharma's market capitalisation today?

Urogen Pharma market capitalisation is $0.00T as on .

How to invest in Urogen Pharma Stock (URGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Urogen Pharma on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Urogen Pharma Shares that will get you 0.0320 shares as per Urogen Pharma share price of $46.86 per share as on August 22, 2026 at 8:45 am IST.

What is the minimum amount required to buy Urogen Pharma Stock (URGN) from India?

Indian investors can start investing in Urogen Pharma (URGN) shares with as little as ₹95.71 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.10 in Urogen Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Urogen Pharma share’s latest price of $46.86 as on August 22, 2026 at 8:45 am IST, you will get 0.2134 shares of Urogen Pharma. Learn more about fractional shares .

What are the returns that Urogen Pharma has given to Indian investors in the last 5 years?

Urogen Pharma stock has given 225.81% share price returns and 29.1% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?